세계의 칼시필락시스(Calciphylaxis) 치료 시장 보고서(2025년)
Calciphylaxis Treatment Global Market Report 2025
상품코드 : 1824601
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

칼시필락시스(Calciphylaxis) 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.3%를 나타내 28억 달러로 성장할 전망입니다. 예측 기간의 성장 배경으로는 건강 관리 지출 증가, 협업 및 파트너십 증가, 개인화된 의료 지원, 규제 당국 지원 및 신속한 승인, 환자 중심 건강 관리 접근법이 있습니다. 예측 기간의 주요 동향으로는 새로운 치료법, 진단 진보, 연구 개발 증가, 공동 이니셔티브, 환자 중심 접근법, 규제 상황 역학 등이 있습니다.

향후 5년간의 성장률 8.3%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 프랑스와 이스라엘에서 조달하는 고기압 산소 치료 시스템과 비스포스포네이트 제형의 비용을 밀어 올려 이 생명을 위협하는 질환의 치료비를 악화시킴으로써 미국의 혈관 의료에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

신장병의 유병률 증가가 예상되어 칼시필락시스(Calciphylaxis) 치료 시장 성장을 견인합니다. 신장병은 노폐물과 여분의 수분을 여과하는 중요한 기능에 영향을 미치고, 칼슘이나 인산의 대사를 저해하여 칼시필락시스(Calciphylaxis)의 위험을 높입니다. 2023년 영국의 만성 신장병 환자 수는 719만명으로 인구의 10% 이상을 차지했고 2033년에는 761만명에 달할 것으로 예상되므로 신장병 유병률 증가가 칼시필락시스(Calciphylaxis) 치료 시장의 주요 촉진요인이 될 전망입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and severe medical condition characterized by the deposition of calcium in small blood vessels and tissues. It primarily affects individuals with kidney disease, especially those with end-stage renal disease (ESRD). The treatment approach involves pain management and nutritional support therapies to address symptoms such as painful and non-healing skin ulcers, tissue necrosis, and potential complications such as sepsis, which can pose life-threatening risks.

The main types of calciphylaxis treatment include medication, hyperbaric oxygen therapy, and other interventions. Medication involves the use of pharmaceutical drugs to manage symptoms and underlying causes. Medications such as sodium thiosulfate, opioids, or non-opioid drugs may be employed to treat or prevent infections, manage pain, and address aspects associated with calciphylaxis. Diagnosis is typically carried out through imaging, blood tests, and deep skin biopsies performed by end users such as hospitals, clinics, medical research centers, and academic institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The calciphylaxis treatment market research report is one of a series of new reports from The Business Research Company that provides calciphylaxis treatment market statistics, including calciphylaxis treatment industry global market size, regional shares, competitors with an calciphylaxis treatment market share, detailed calciphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis treatment industry. This calciphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calciphylaxis treatment market size has grown strongly in recent years. It will grow from $1.86 billion in 2024 to $2.03 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing incidence of calciphylaxis, rising awareness among healthcare professionals, expanding healthcare infrastructure, clinical research and drug development.

The calciphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising healthcare expenditure, increasing collaboration and partnerships, focus on personalized medicine, regulatory support and expedited approvals, patient-centric healthcare approaches. Major trends in the forecast period include emerging therapeutic modalities, diagnostic advancements, increased research and development, collaborative initiatives, patient-centric approaches, regulatory landscape dynamics.

The forecast of 8.3% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. vascular medicine by driving up the cost of hyperbaric oxygen therapy systems and bisphosphonate formulations sourced from France and Israel, exacerbating treatment costs for this life-threatening condition. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the prevalence of kidney diseases is set to drive the growth of the calciphylaxis treatment market. Kidney diseases, affecting the vital function of filtering waste products and excess fluids, disrupt calcium and phosphate metabolism, increasing the risk of calciphylaxis. With an estimated 7.19 million people affected by chronic kidney disease in the UK in 2023, representing over 10% of the population and expected to reach 7.61 million by 2033, the growing prevalence of kidney diseases will be a key driver for the calciphylaxis treatment market.

The expansion of ongoing clinical trials is expected to further boost the calciphylaxis treatment market. Clinical trials play a pivotal role in assessing the safety and efficacy of potential treatments, contributing valuable evidence for improved therapeutic approaches. With the number of registered studies increasing from 437,523 in 2022 to 468,457 in 2023 globally, the ongoing clinical trials provide essential insights and advancements in the medical understanding and treatment of calciphylaxis, contributing to the market's growth.

Leading companies in the calciphylaxis treatment market are focusing on developing advanced diagnostic techniques and health evaluation services to enhance profitability. By introducing comprehensive in-home kidney health evaluations, companies such as Signify Health, Inc. aim to provide convenient and proactive monitoring solutions for kidney health. Such initiatives, including urinalysis and estimated glomerular filtration rate assessments, prove valuable in early detection and management of chronic kidney health issues, including conditions such as calciphylaxis.

In January 2024, Merck KGaA, a Germany-based science and technology company providing calciphylaxis treatment, partnered with Inspirna Inc. Through this partnership, Merck KGaA expanded its colorectal cancer portfolio via a licensing agreement for the drug ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently in Phase II development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a U.S.-based clinical-stage biopharmaceutical company.

Major companies operating in the calciphylaxis treatment market report are Pfizer Inc., Merck And Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, 3M Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Novo Nordisk, Viatris (Mylan N.V.), Regeneron Pharmaceuticals Inc., Smith And Nephew Plc., Incyte Corporation, ConvaTec Inc., Vifor Pharma Group, BSN Medical GmbH, Panion And BF Biotech Inc., Inozyme Pharma Inc., Sanifit Therapeutics S.A, Hope Pharmaceuticals, Menlo Therapeutics

North America was the largest region in the calciphylaxis treatment market in 2024 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the calciphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calciphylaxis treatment market consists of revenues earned by entities by providing diagnostic services such as infrared thermography, electrolyte and mineral analysis, and measuring serum parathyroid hormone (PTH) levels to diagnose and assess the severity of calciphylaxis in patients. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis treatment market also includes sales of intensive wound care, clot-dissolving therapy, and vitamin K therapy, which are comprehensive treatment approaches for managing calciphylaxis. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calciphylaxis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calciphylaxis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for calciphylaxis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The calciphylaxis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Calciphylaxis Treatment Market Characteristics

3. Calciphylaxis Treatment Market Trends And Strategies

4. Calciphylaxis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Calciphylaxis Treatment Growth Analysis And Strategic Analysis Framework

6. Calciphylaxis Treatment Market Segmentation

7. Calciphylaxis Treatment Market Regional And Country Analysis

8. Asia-Pacific Calciphylaxis Treatment Market

9. China Calciphylaxis Treatment Market

10. India Calciphylaxis Treatment Market

11. Japan Calciphylaxis Treatment Market

12. Australia Calciphylaxis Treatment Market

13. Indonesia Calciphylaxis Treatment Market

14. South Korea Calciphylaxis Treatment Market

15. Western Europe Calciphylaxis Treatment Market

16. UK Calciphylaxis Treatment Market

17. Germany Calciphylaxis Treatment Market

18. France Calciphylaxis Treatment Market

19. Italy Calciphylaxis Treatment Market

20. Spain Calciphylaxis Treatment Market

21. Eastern Europe Calciphylaxis Treatment Market

22. Russia Calciphylaxis Treatment Market

23. North America Calciphylaxis Treatment Market

24. USA Calciphylaxis Treatment Market

25. Canada Calciphylaxis Treatment Market

26. South America Calciphylaxis Treatment Market

27. Brazil Calciphylaxis Treatment Market

28. Middle East Calciphylaxis Treatment Market

29. Africa Calciphylaxis Treatment Market

30. Calciphylaxis Treatment Market Competitive Landscape And Company Profiles

31. Calciphylaxis Treatment Market Other Major And Innovative Companies

32. Global Calciphylaxis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calciphylaxis Treatment Market

34. Recent Developments In The Calciphylaxis Treatment Market

35. Calciphylaxis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기